Q-omics provides the consensus-scored ADAD2 profile across patient tissues and cancer cell-line models. ADAD2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ADAD2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ADAD2 RNA expression shows 13,382 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, KIRC, and GBM as cancer lineages where ADAD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAD2 survival associations across molecular data types. ADAD2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAD2 RNA expression–survival associations across cancer types. High ADAD2 expression shows unfavorable associations in COAD, ACC, KIRC and MESO, but favorable associations in HNSC and THCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ADAD2 RNA expression.
This table summarizes ADAD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAD2 shows lower tumor expression in KIRC, KICH, UCEC, BRCA and KIRP and higher tumor expression in LUSC. The KIRC box plot shows higher ADAD2 RNA expression in normal versus tumor tissue (log2 FC = −0.212, t-test p < 0.001).
This table shows molecular features associated with ADAD2 in patient tissues and cancer cell lines. In patient samples, ADAD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
